MBCProject_3717_T2_RNA
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.510
- INTERFERON_GAMMA_RESPONSE+0.400
- E2F_TARGETS+0.380
- INTERFERON_ALPHA_RESPONSE+0.370
- OXIDATIVE_PHOSPHORYLATION+0.310
- ALLOGRAFT_REJECTION+0.290
- MYC_TARGETS_V1+0.280
- MTORC1_SIGNALING+0.260
- DNA_REPAIR+0.230
- UNFOLDED_PROTEIN_RESPONSE+0.210
Top 10 suppressed
- NOTCH_SIGNALING-0.470
- UV_RESPONSE_DN-0.460
- WNT_BETA_CATENIN_SIGNALING-0.440
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.410
- TGF_BETA_SIGNALING-0.380
- MITOTIC_SPINDLE-0.300
- HEME_METABOLISM-0.290
- COAGULATION-0.250
- ANDROGEN_RESPONSE-0.230
- ANGIOGENESIS-0.230
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8518323 | — | E | 0.853 |
| 2 | TCGA-A2-A4S3-01A-21R-A266-07 | — | B | 0.848 |
| 3 | SRR8518297 | — | E | 0.839 |
| 4 | SRR8518144 | — | E | 0.837 |
| 5 | MBCProject_0454_T1_RNA | — | B | 0.833 |
| 6 | BS_MMNRZ1EQ | ATRT | — | 0.824 |
| 7 | SRR8518289 | — | E | 0.823 |
| 8 | MBCProject_3717_T3_RNA | — | B | 0.822 |
| 9 | TCGA-58-8387-01A-11R-2296-07 | — | cohortSQ2 | 0.819 |
| 10 | 20020093.Her2HRneg | — | E | 0.819 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.510 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.400 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.380 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.370 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.310 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.290 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.280 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.260 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.230 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.210 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.200 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.190 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.130 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.130 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.110 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.060 | Remibrutinib | — uncovered |
| PEROXISOME | 0.060 | Idelalisib | — uncovered |
| COMPLEMENT | 0.030 | Inavolisib | — uncovered |